Sminu Bose

Sminu Bose

Auto-generated profile, based on publicly available information

Sminu Bose

Memorial Sloan Kettering Cancer Center 1 Gynecologic Medical Oncology Service, Department of Medicine New York, New York

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Cell Metabolism
Verified
Journal Article
Closed access
ALAnne Le
Anne Le
ALAndrew N. Lane
Andrew N. Lane
MHMax Hamaker
Max Hamaker
SBSminu Bose
Sminu Bose
AGArvin Gouw
Arvin Gouw
CDChi V. Dang
Chi V. Dang

27 June 2018
Verified
Book Chapter
Closed access
PDF file
SBSminu Bose
Sminu Bose
ALAnne Le
Anne Le

1 September 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MIMatthew Ingham
Matthew Ingham
JAJacob B. Allred
Jacob B. Allred
LCLi Chen
Li Chen
BDBiswasjit Das
Biswasjit Das
BKBose Kochupurakkal
Bose Kochupurakkal
GSGary K. Schwartz
Gary K. Schwartz
PURPOSE: Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified homologous recombination deficiency in uLMS. In preclinical studies where olaparib and temozolomide provided modest activity, the combination was highly effective for inhibiting uLMS tumor growth. PATIENTS AND METHODS: NCI Protocol 10250 is a single-arm, open-label, multicenter, phase II study evaluating olaparib and temozolomide in advanced uLMS. Patients with progression on ≥1 prior line received temozolomide 75 mg/m2 orally once daily with olaparib 200 mg orally twice a day both on days 1-7 in 21-day cycles. The primary end point was the best objective response rate (ORR) within 6 months. A one-stage binomial design was used. If ≥5 of 22 responded, the treatment would be considered promising (93% power; α = .06). All patients underwent paired biopsies that were evaluated with whole-exome sequencing (WES)/RNAseq and a RAD51 foci formation assay. RESULTS: Twenty-two patients were evaluable. The median age was 55 years, and 59% had received three or more prior lines. Best ORR within 6 months was 23% (5 of 22). The overall ORR was 27% (6 of 22). The median progression-free survival (mPFS) was 6.9 months (95% CI, 5.4 months to not estimable). Hematologic toxicity was common (grade 3/4 neutropenia: 75%; thrombocytopenia: 32%) but manageable with dose modification. Five of 16 (31%) of tumors contained a deleterious homologous recombination gene alteration by WES, and 9 of 18 (50%) were homologous recombination-deficient by the RAD51 assay. In an exploratory analysis, mPFS was prolonged for patients with homologous recombination-deficient versus homologous recombination-proficient tumors (11.2 v 5.4 months, P = .05) by RAD51. CONCLUSION: Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.


31 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KLKaran Luthria
Karan Luthria
PSParin Shah
Parin Shah
BCBlake Caldwell
Blake Caldwell
JMJohannes C. Melms
Johannes C. Melms
SASinan Abuzaid
Sinan Abuzaid
BIBenjamin Izar
Benjamin Izar
Purpose: Sarcoma encompasses a diverse group of cancers that are typically resistant to current therapies, including immune checkpoint blockade (ICB), and underlying mechanisms are poorly understood. The contexture of sarcomas limits generation of high-quality data using cutting-edge molecular profiling methods, such as single-cell RNA-sequencing, thus hampering progress in understanding these understudied cancers. Experimental Design: Here, we demonstrate feasibility of producing multimodal single-cell genomics and whole-genome sequencing data from frozen tissues, profiling 75,716 cell transcriptomes of five undifferentiated pleomorphic sarcoma and three intimal sarcoma samples, including paired specimens from two patients treated with ICB. Results: We find that genomic diversity decreases in patients with response to ICB, and, in unbiased analyses, identify cancer cell programs associated with therapy resistance. Although interactions of tumor-infiltrating T lymphocytes within the tumor ecosystem increase in ICB responders, clonal expansion of CD8+ T cells alone was insufficient to predict drug responses. Conclusions: This study provides a framework for studying rare tumors and identifies salient and treatment-associated cancer cell intrinsic and tumor microenvironmental features in sarcomas.

25 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MRMaria M. Rubinstein
Maria M. Rubinstein
JGJennifer Y. Ge
Jennifer Y. Ge
QZQin Zhou
Qin Zhou
AIAlexia Iasonos
Alexia Iasonos
BWBritta Weigelt
Britta Weigelt
VMVicky Makker
Vicky Makker
Purpose: Copy number–high (CN-H)/p53-abnormal endometrial cancers are high-grade uterine malignancies characterized by TP53 mutations, copy-number alterations, mismatch repair proficiency (MMRp), and absence of POLE mutations. A subset may be homologous recombination deficient (HRD), potentially conferring sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. We aimed to test the combination of PARP and immune checkpoint inhibitors in this subgroup, leveraging possible synergy from immune priming. Patients and Methods: We conducted a single-arm, open-label, phase II trial evaluating the efficacy and safety of olaparib (300 mg orally twice daily) plus pembrolizumab (200 mg intravenously every 3 weeks) in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Eligible patients had p53-abnormal, MMRp, and POLE-negative disease and up to 3 prior lines of therapy. The primary endpoint was the best overall response rate (ORR) at 24 weeks. Results: Of the 25 patients evaluable for efficacy, 2 patients achieved a complete response, and 6 achieved a partial response, resulting in an ORR of 32% [90% one-sided confidence interval (CI), 19.6%–100%]. The median duration of response was 11.2 months (80% two-sided CI, 6.4–11.9). The median progression-free survival was 3.9 months (80% two-sided CI, 2.1–5.8), and the median overall survival was 16.5 months (80% two-sided CI, 9.6–23.6). No new safety signals were identified. Genomic analyses suggested that responders had a numerically higher frequency of HRD tumors than nonresponders (50% vs. 17%). Conclusions: The combination of olaparib plus pembrolizumab has promising activity with durable responses in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Molecular biomarkers may be helpful for patient selection in future studies of this combination.